logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Atea Pharmaceuticals, Inc.


USPTO Granted Patents = 28


Forward Citations = 151

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Jean-Pierre Sommadossi (27 out of 77 patents)

silverMedal Adel M Moussa (27 out of 64 patents)

bronzeMedal Xiao-Jian Zhou (2 out of 2 patents)

4.  Keith M Pietropaolo (2 out of 2 patents)

5.  Ashleigh Shannon (1 out of 1 patent)

6.  Adel Moussa (1 out of 1 patent)

7.  Kai Lin (1 out of 1 patent)

8.  Bruno Canard (1 out of 1 patent)


Core Competencies:
SARS-CoV-2
Hepatitis C Virus
Nucleotide
Hemi-Sulfate Salt
Purine Nucleotides
Combination Therapy
COVID-19
Active Compounds
RNA Virus Treatment
Morphic Form
Therapeutics

28 patents:

1. 12746251 - NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY (2026-09-29),
2. 12741984 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus (2026-09-22),
3. 12686697 - Advantageous morphic form of AT-527 hemi-sulfate salt (2026-07-21),
4. 12551499 - Highly active compounds against COVID-19 (2026-02-17),
5. 12458656 - Advantageous anti-HCV combination therapy (2025-11-04),
6. 12226429 - Highly active compounds against COVID-19 (2025-02-18),
7. 12084473 - β-D-2'-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment (2024-09-10),
8. 12006340 - Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus (2024-06-11),
9. 11975016 - 2′-substituted-N-substituted purine nucleotides for RNA virus treatment (2024-05-07),
10. 11813278 - Highly active compounds against COVID-19 (2023-11-14),
11. 11738038 - Highly active compounds against COVID-19 (2023-08-29),
12. 11707480 - Highly active compounds against COVID-19 (2023-07-25),
13. 11690860 - Treatment of HCV infected patients with cirrhosis (2023-07-04),
14. 10946033 - 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment (2021-03-16),
15. 10906928 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus (2021-02-02),
Company Overview
Atea Pharmaceuticals, Inc. is a biotechnology company based in Boston, MA, focused on developing innovative antiviral therapies. The company specializes in the discovery and advancement of treatments for viral infections, particularly those caused by RNA viruses. Atea leverages its proprietary technology platform to create novel compounds aimed at addressing significant unmet medical needs in infectious diseases. Through its research efforts, Atea aims to improve patient outcomes and contribute to the global fight against viral pathogens.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

28 Patents

#90 in Boston, MA

#715 in Massachusetts

#12,016 in US

#23,299 in the World

Boston, MA (US)
Boston, MA, United States of America

Atea Pharmaceuticals, Inc.

Forward Citations = 151

8 inventors:

goldMedal Jean-Pierre Sommadossi (27 out of 77 patents)

silverMedal Adel M Moussa (27 out of 64 patents)

bronzeMedal Xiao-Jian Zhou (2 out of 2 patents)

4.  Keith M Pietropaolo (2 out of 2 patents)

5.  Ashleigh Shannon (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Atea Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/atea-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…